Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464925 | 0.90 | YTHDC1 (0.51) | HDAC6HSP90AA1HSP90AB1HDAC1HDAC4 | |
| SCHEMBL2060052 | 0.87 | YTHDC1 (0.57) | YTHDC1 | |
| SCHEMBL5464136 | 0.83 | TLR7 (0.47) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL3394076 | 0.83 | HSP90AB1 (0.68) | HDAC6HSP90AA1HSP90AB1HDAC1HDAC4 | |
| SCHEMBL5467025 | 0.80 | TLR7 (0.45) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL5463457 | 0.80 | TLR7 (0.51) | HDAC1HDAC2ADORA2AADORA1YTHDC1 | |
| SCHEMBL2060130 | 0.79 | TLR7 (0.66) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL5465289 | 0.79 | TLR7 (0.52) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL5469427 | 0.79 | TLR7 (0.56) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL3395646 | 0.79 | HDAC6 (0.73) | HDAC6HSP90AA1HSP90AB1HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1728792-A1 | 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | HDAC6 1513/4885HSP90AA1 4142/4885HSP90AB1 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.